Finally, telisotuzumab vedotin (Teliso-V), an ADC composed of a Met antibody (ABT-700) and a microtubule inhibitor (monomethyl auristatin E), is being explored in the LUMINOSITY trial (NCT03539536) that is currently recruiting pretreated patients with EGFR-mutant NSCLC and immunohistochemically positive c-MET. This evidence concerns the gene MET and non-small cell lung carcinoma.